FM CONFERENCE AND PAMPERS 2011 ANOTHER BIG HIT

News of successful 2012 FM Conference and date for 2012 FibCon and Pampers in the Cathedral town of Chichester, West Sussex, UK.

A ‘WIN WIN’ FIBROMYALGIA CONFERENCE

News from the world of fibromyalgia. Leading speakers at SE England fibromyalgia conference share their insights into the brains of fibromites, sleep patterns and their diets.

Back Pain – Medication and Addiction

From the FMS Global News Desk of Jeanne Hambleton (UK) Courtesy of WebMD.com How can we balance the risk of drug abuse with the suffering caused by untreated back pain? By R. Morgan Griffin – Reviewed by Brunilda Nazario, MD – WebMD Feature People living with serious back pain have to sort through a lot [...]

Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments

From the FMS Global News Desk of Jeanne Hambleton (UK) First Large, Placebo-Controlled Study to Demonstrate Efficacy of Lyrica as Add-on Therapy Strategy in Difficult-to-Treat GAD Patients May 19, 2009 03:00 PM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–The addition of Pfizer’s Lyrica® (pregabalin) capsules CV to other generalized anxiety disorder (GAD) treatments significantly improved the [...]

FDA Requires Additional Labelling for Over-the-Counter Pain Relievers and Fever Reducers to Help Consumers Use Products Safely

From the FMS Global News Desk of Jeanne Hambleton (UK) Courtesy FDA US Food and Drugs Administration – For Immediate Release The Food and Drug Administration issued a final rule today that requires manufacturers of over-the-counter (OTC) pain relievers and fever reducers to revise their labelling to include warnings about potential safety risks, such as [...]

Fibromyalgia and Epilepsy Drug Lyrica Helps Restless Leg Sufferers, Researchers Say

From the FMS Global News Desk of Jeanne Hambleton (UK) Courtesy of attorneyatlaw.com Legal Briefs Lyrica, the Pfizer drug for treatment of the chronic pain disorder fibromyalgia and preventing epileptic seizures, also appears to benefit people who cannot get to sleep because of restless legs syndrome, new findings suggest. A recently completed clinical trial found [...]

Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show

From the FMS Global News Desk of Jeanne Hambleton (UK) SEATTLE–(BUSINESS WIRE) Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo, according to new data presented today at the American Academy of Neurology annual meeting. The data also showed that patients treated [...]

Still no treatment in Europe for the 14 million FMS patients trapped in pain!

From the FMS Global News Desk of Jeanne Hambleton (UK) Press Release from ENFA – 29.04.2009 Brussels, (29.04.2009) Last week was high on activities for the Fibromyalgia community, on one hand the European Network of Fibromyalgia Associations (ENFA) met with the European Health Commissioner Ms Androulla Vassiliou1. And on the other hand the European Medicines [...]

Alert: MedWatch – Digoxin (Caraco brand) – Recall of tablets because they may differ in size

Caraco Pharmaceutical Laboratories and FDA notified healthcare professionals of a consumer-level recall of Caraco brand Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011. The tablets are being recalled because they may differ in size and [...]

Chronic Opioid Therapy Guidelines Offer Direction for Physicians

From the FMS Global News Desk of Jeanne Hambleton Courtesy of Fibromyalgia Network – February 2009 While patients are rightfully concerned about not receiving adequate pain relief, physicians harbor fears about drug abuse, safety issues, and government oversight. New clinical guidelines for the use of chronic opioid therapy in chronic non-cancer pain patients, developed by [...]